Analysts Conflicted on These Healthcare Names: PolarityTE Inc (NASDAQ: PTE), Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) and Hologic (NASDAQ: HOLX)

By Ryan Adsit

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PolarityTE Inc (PTEResearch Report), Spring Bank Pharmaceuticals Inc (SBPHResearch Report) and Hologic (HOLXResearch Report).

PolarityTE Inc (PTE)

Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on PolarityTE Inc yesterday and set a price target of $65. The company’s shares closed yesterday at $9.11, close to its 52-week low of $7.87.

Piros noted:

“We believe that PolarityTE can revolutionize the field of regenerative medicine. We think SkinTE can achieve over $700 million revenue, with perhaps multiples of this number when adding bone, cartilage, heart and muscle products in development. We reiterate our OW rating. 12-month price target is derived from the combined risk-adjusted NPV of potential future cash flows from the SkinTE product and an enterprise value for the follow-on product lines.”

According to TipRanks.com, Piros is a 1-star analyst with an average return of -0.8% and a 47.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on PolarityTE Inc is a Strong Buy with an average price target of $39, which is a 328.1% upside from current levels. In a report issued on April 25, Northland Securities also assigned a Buy rating to the stock with a $50 price target.

See today’s analyst top recommended stocks >>

Spring Bank Pharmaceuticals Inc (SBPH)

In a report released yesterday, Taylor Feehley from Chardan Capital reiterated a Buy rating on Spring Bank Pharmaceuticals Inc, with a price target of $25. The company’s shares closed yesterday at $7, close to its 52-week low of $6.30.

Feehley wrote:

“We may obtain greater visibility on sAg reduction and other markers of viral clearance when the Gilead (unrated)- run phase II trial of inarigivir plus Vemlidy (NCT03434353) reads out, which Spring Bank indicates could be in 2H19, although inarigivir was only administered to a maximum of 200mg in this trial which may not provide fully optimal results.”

According to TipRanks.com, Feehley is a 1-star analyst with an average return of -3.5% and a 45.5% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Kaleido Biosciences Inc, Evelo Biosciences Inc, and Assembly Biosciences.

Currently, the analyst consensus on Spring Bank Pharmaceuticals Inc is a Strong Buy with an average price target of $26.

Hologic (HOLX)

Canaccord Genuity analyst Mark Massaro maintained a Hold rating on Hologic yesterday and set a price target of $45. The company’s shares closed yesterday at $45.59.

Massaro noted:

“We remain neutral on Hologic as a result of the company’s “slow growth” top line outlook of approximately +3%; gross margin pressures; and concerns about the company’s disappointing Cynosure division. Earlier this year, it seemed that investors were willing to overlook negative growth from Cynosure (which admittedly is ~10% of its revenue); however, it seems that investor concerns have resurfaced a bit about this division’s pro-forma growth. We acknowledge we think the downside is low on HOLX (we love the breast health and molecular diagnostics franchises), but given that we don’t love the Cynosure business and are concerned that the company isn’t out of the woods yet on Cyno, ongoing pressures to GMs, and a moderate ~3% growth rate overall, we reiterate our Hold rating and $45 PT on HOLX. FQ2/19 preview. We look for FQ2 adj.”

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.9% and a 60.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.

Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $48.20.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.